NIH Funding Opportunities

Advancing Genomic Medicine Research (R03 Clinical Trial Not Allowed)

Funding Opportunity RFA-HG-23-048 from the NIH Guide for Grants and Contracts. This NOFO solicits applications that stimulate innovation and advance understanding of when, where and how best to implement the use and sharing of genomic information and technologies in clinical care in all persons irrespective of racial/ethnic background or socioeconomic status. The R03 grant mechanism supports small research projects that can be carried out in a short period of time with limited resources, such as pilot or feasibility studies; secondary analysis of existing data; small, self-contained research projects; or development of research methodology. An R03 grant application need not have extensive background material or preliminary information. Accordingly, reviewers will emphasize the conceptual framework, the level of innovation, and the potential to significantly advance our knowledge or understanding. Appropriate justification for the proposed work can be provided through literature citations, data from other sources, or, when available, from investigator-generated data. Preliminary data are not required for R03 applications; however, they may be included if available.

Advancing Genomic Medicine Research (R21 Clinical Trial Optional)

Funding Opportunity RFA-HG-23-033 from the NIH Guide for Grants and Contracts. The National Human Genome Research Institute intends to issue a Funding Opportunity Announcement (FOA) to solicit applications that stimulate innovation and advance understanding of when, where and how best to implement the use and sharing of genomic information and technologies in clinical care in all persons including populations or communities that experience health disparities, such as racial or ethnic minority groups, people with lower socioeconomic (SES) status, underserved rural communities, and sexual and gender minority groups. The intended FOA will be based on a concept recently approved by the National Advisory Council on Human Genome Research and accompanying discussion. This Notice is being provided to allow potential applicants sufficient time to responsive projects. Details of the planned FOA are provided below.

Multi-sectoral preventive interventions that address social determinants of health in populations that experience health disparities (UG3/UH3, Clinical Trial Required)

Funding Opportunity PAR-24-053 from the NIH Guide for Grants and Contracts. The purpose of this NOFO is to support projects to test prospective multi-sectoral preventive interventions that address social determinants of health in populations that experience health disparities. These research projects will be part of the Multi-Sectoral Preventive Interventions (MSPI) Research Network, which will also include a Coordinating Center (NOFO xxx). Funded under a cooperative agreement, projects participating in the MSPI Research Network will collaborate to share approaches, methods, and data, working closely with NIH Institutes, Offices and Centers. Applicants applying to this NOFO are encouraged to review the Coordinating Center NOFO to fully understand the MSPI Research Network structure and activities. This NOFO solicits bi-phasic research projects proposed in UG3/UH3 Phased Innovation Awards Cooperative Agreement applications. Funding for the UG3 phase (phase I) will be used to demonstrate sufficient preparation, feasibility and capacity to meet foundational milestone targets specific to the work proposed. A UG3 project that meets its milestones will be administratively considered by NIH and prioritized for transition to the UH3 award (phase II). Applicants responding to this NOFO must address specific aims and milestones for both the UG3 and UH3 phases.

Advancing Genomic Medicine Research (R01 Clinical Trial Optional)

Funding Opportunity RFA-HG-23-032 from the NIH Guide for Grants and Contracts. The National Human Genome Research Institute intends to issue a Funding Opportunity Announcement (FOA) to solicit applications that stimulate innovation and advance understanding of when, where and how best to implement the use and sharing of genomic information and technologies in clinical care in all persons including populations or communities that experience health disparities, such as racial or ethnic minority groups, people with lower socioeconomic (SES) status, underserved rural communities, and sexual and gender minority groups.

HEAL Initiative: Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program (R01 Clinical Trial Optional)

Funding Opportunity RFA-DA-23-059 from the NIH Guide for Grants and Contracts. Sleep and circadian dysfunctions are frequently co-morbid with opioid use disorder (OUD) and may have clinical utility in identifying individuals at risk for poor treatment response and relapse. The goals of this program are a) to uncover novel mechanisms underlying the bidirectional interrelationship between sleep/circadian rhythm and OUD, and b) to reveal new insights into sleep and/or circadian-based predictors of OUD medication treatment response and outcomes.

HEAL Initiative - Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program: Leadership and Data Co-ordinating Center (U01 Clinical Trial Optional)

Funding Opportunity RFA-DA-23-060 from the NIH Guide for Grants and Contracts. Applications are invited from institutions to participate as the Leadership and Data Coordinating Center (LDCC) for the Sleep Predictors of Opioid Use Disorders (OUD) Treatment and Outcomes Program. The overall goals of this program are a) to uncover novel mechanisms underlying the bidirectional interrelationship between sleep/circadian rhythm and OUD, and b) to delineate sleep and/or circadian-based predictors of OUD treatment response and outcomes. The Leadership and Data Coordination Center will lead, coordinate and analyze data for a multi-site common protocol focused on sleep/circadian rhythm measures. The data will be used to develop a predictive model of OUD medication treatment response and outcomes.

Páginas